Vyome Holdings, Inc. (HIND)

♥ 344 Thanks from members

Vyome Holdings, Inc. (HIND) reported a fiscal Q1 2026 loss per share of -$0.15, beating the consensus estimate of -$0.1836 by 18.3%. Despite the narrower-than-expected loss, market reaction remained muted as the beat failed to lift the stock price.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Vyome Therapeutics Team Leadership: Shiladitya Sengupta (CEO) Holder: Institutional Venture Capitalists Holder: Founders and Insiders Topical anti-inflammatory treatments Dermatology pipeline drugs #Vyome Holdings #HIND stock #biotech company #dermatology therapeutics #clinical stage pharma